U.S. & Canada Skin Cancer Dermatology Market Size, Share, & Trends 2030
The U.S. & Canada Skin Cancer Dermatology market size was valued at US$ 2.07 billion in 2021 and is expected to hit US$ 3.4 Billion by 2030, growing at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030.
Growth Factors:
The growing prevalence of skin cancer is contributing largely to the high market demand. Furthermore, growing awareness among people about skin cancer and technological advancements in the dermatology field is also considered as the important factors driving the market growth. The skin cancer dermatology markets in U.S. and Canada witnessed a negative impact during the COVID-19 pandemic as dermatology practices and medical supply chains were hampered.
According to a One Access journal called Plos One, Ontario Province in Canada witnessed a precipitous drop in total skin biopsies (15% of expected) with the onset of COVID-19 cases, and the majority of the females in the region were less likely to be biopsied during the pandemic. However, the rates of biopsy increased substantially in the second half of 2020. According to the American Academy of Dermatology, 3.3 million people in the U.S. are diagnosed with basal and squamous cell skin cancers. Moreover, it is estimated that one in every five individuals in the U.S. is likely to be diagnosed with skin cancer in their lifetime. Meanwhile, in 2019, in Canada, nearly 7,800 melanoma cases and nearly 1,300 deaths due to the same were reported.
The high incidence rate of melanoma in Canada and the U.S. is anticipated to fuel market growth. The U.S diagnostic imaging test type segment is expected to witness the fastest growth rate of 6.7% during the forecast period. The presence of organizations that aim to increase awareness regarding skin cancer and reduce its incidence rate is anticipated to fuel market growth. The American Academy of Dermatology (AAD) intends to reduce skin cancer-related incidence and mortality by educating the public about the techniques that aid in minimizing the risk of skin cancer and facilitate them in the identification of skin cancer or a potentially cancerous skin lesion.
AAD also aims to set high clinical practice standards and undertake public awareness programs and research activities in the field of dermatology to enhance patient care whereas the Canadian Dermatology Association aims to increase public awareness levels regarding sun protection and prevention of skin cancer. Technology plays a key role in the clinical decision-making behavior of dermatologists. The introduction of teledermatology and the growing number of smartphone-compatible diagnostic devices has enabled dermatologist to undertake remote patient diagnosis and monitoring, thus reducing the number of unnecessary office procedures. Furthermore, the EHR technology also enables dermatologists to select a cost-effective therapy for the patient.
The advent of COVID-19 impacted the operations and supply of many critical medical devices in 2020. Agilent Technologies stated that they faced supply-chain bottlenecks during the pandemic and the revenue growth was slower than forecasted. However, after the lockdown eased in the second quarter of 2020, the company recovered from the losses and reported strong financial performance despite the turbulence caused by COVID-19. The International Dermoscopy Society reported that the outbreak had a negative impact on most dermatology services, with a significant reduction in consultation time spent for chronic patients, and an increased risk of missed melanoma and nonmelanoma skin cancer.
Report Scope of the U.S. & Canada Skin Cancer Dermatology Market
|
Report Coverage |
Details |
|
Market Size in 2021 |
USD 2.07 Billion |
|
Revenue Projection By 2030 |
USD 3.4 Billion |
|
Growth Rate |
CAGR of 5.9% from 2022 to 2030 |
|
Base Year |
2021 |
|
Historical data |
2017 - 2020 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Test type, facility type, age group |
|
Companies Mentioned |
Firefly; SkinIO; Canfield Scientific, Inc.; FotoFinder Systems, Inc.; 3Gen; MetaOptima; Agilent Technologies; SkinVision; Speclipse, Inc.; Skin Analytics |
COVID-19 Impact Assessment on Market Landscape
Test Type Insights
On the basis of test types, the market is further segmented into skin biopsy, dermatoscopy, diagnostic imaging, and lymph node biopsy. The skin biopsy test type segment held the largest market share of 32.3% in 2021. Skin biopsy is a procedure where a small amount of tissue is removed from the targeted area for examination under a microscope. This can be attributed to the adoption of this procedure for the diagnosis of a wide range of skin conditions, such as melanoma, skin infection, skin tags, dermatitis, basal cell carcinoma, and squamous cell carcinoma. A biopsy is often the only test needed to diagnose and find out the stage, or extent, of cancer.
The diagnostic imaging segment is anticipated to grow at the fastest CAGR over the forecast period due to the introduction of advanced non-invasive techniques, such as laser scanning confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz pulsed imaging, magnetic resonance imaging, and photoacoustic microscopy, which have increased the accuracy of diagnosis. Furthermore, the combination of RCM with dermatoscopes is also expected to enhance the accuracy of diagnosis and aid in the differentiation between malignant and benign skin cancers.
Facility Type Insights
On the basis of facility types, the market has been further divided into stand-alone practices, multispecialty clinics, dermatology groups, hospital Outpatient Departments (OPDs), and others. The hospital OPD facility type segment held the largest market share of 40.2% in 2021 and is also expected to witness the fastest growth rate from 2022 to 2030. The purchase of devices in large numbers accompanied by the high demand for healthcare services and procedures in this setting is considered to play a vital role in the growth of the hospital OPD segment over the coming years. The presence of public insurance systems and the availability of advanced technologies and procedures in hospitals are also expected to drive the segment growth.
The multispecialty clinics and dermatology group segments held relatively higher market shares than the stand-alone practices segment in 2021. This can be attributed to the increased costs and complexities of solo practices along with relatively higher dermatologist compensation in the group setting and higher bargaining power of group practices. Multispecialty clinic offers a comprehensive range of effective services and diagnosis of cancer treatments, which allows effective treatment plans and easy patient management. These clinics are equipped with latest, technologically advanced devices and offer 24/7 emergency facilities along with pharmacy, assistance with the blood bank, ICU, NICU, PICU, and ambulance services etc. All these factors are projected to boost the segment's growth.
Age Group Insights
On the basis of age groups, the market has been further categorized into 0-19, 20-39, 40-59, 60-64, 65-74, 75-84, and 85 and above. The 40-59 years age group segment held the highest market share of 26.3% in 2021. This growth was attributed to the high prevalence of skin cancer in this age group as a result of prolonged sun exposure. The 20-39 years age group segment is anticipated to witness the fastest growth rate over the forecast period. The segment’s growth can be attributed to the popularity of tanning equipment and tanning salons among the individuals in this age group.
According to the data published by the AIM at Melanoma Foundation in 2018, the incidence of skin cancer in the population less than 20 years of age is approximately 1%. Skin cancer is the most common form of cancer in the United States and more than 90% of skin cancers are caused by sun exposure. The incidence of melanoma in children increased by 1.7% every year from 1975 to 1994; however, it decreased by 0.6% from 1995 to 2014. Approximately, 400 patients are diagnosed with melanoma each year in population younger than 20 years in the U.S. The increasing sun exposure due to climate change is expected to increase the prevalence of skin cancer among younger population.
Some of the prominent players in the U.S. & Canada Skin Cancer Dermatology Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at U.S. for the period of 2017 to 2030
Key Points Covered in U.S. & Canada Skin Cancer Dermatology Market Study:
Chapter 1 Methodology and Scope
1.1 Segment Market Scope
1.2 Estimates and Forecast Timeline
1.3 Research Methodology
1.3.1 Information procurement
1.3.2 Purchased database:
1.3.3 Nova one advisor’s Internal Database
1.3.4 Secondary sources:
1.3.5 Primary Research:
1.4 List of Primary Sources
1.5 Information Or Data Analysis
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Approach 1: Bottom up Approach
1.8 Objectives
1.8.1 Objective 1:
1.8.2 Objective 2:
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 U.S. Market Variable Analysis
3.2.1 Market driver analysis
3.2.1.1 Increase in the prevalence of skin cancer
3.2.1.2 Exposure to ultraviolet radiation
3.2.1.3 Constant technological advancements in skin cancer diagnostic tests
3.3 Canada Market Variable Analysis
3.3.1 Market driver analysis
3.3.1.1 Increasing incidence of melanoma in Canada
3.3.1.2 Technological advancements
3.3.1.3 Increasing awareness campaigns and supportive government initiatives
3.3.2 U.S. Market restraint analysis
3.3.2.1 Lack of universal health coverage
3.3.3 Canada Market restraint analysis
3.3.3.1 Shortage of medical resources and limited access to healthcare.
3.4 Penetration & Growth Prospect Mapping
3.4.1 U.S. Penetration & Growth Prospect Mapping, By Test Type
3.4.2 Canada Penetration & Growth Prospect Mapping, By Test Type
3.5 Business Environment Analysis tools
3.5.1 SWOT Analysis, by PEST
3.5.2 Porter’s five forces analysis
3.5.3 U.S. & Canada Dermatology Market: Competitive insight
3.5.3.1 Role of concierge medicine/boutique medicine in the dermatology space
3.5.3.2 Advantages of Concierge Medicine:
3.5.3.3 Disadvantages of Concierge Medicine:
3.5.3.4 Role of nurse practitioners and physician assistants in the value chain of skin cancer screening
3.5.3.5 Technological Advancements
3.5.3.6 Decision support systems & Dermatology software
3.5.3.7 Artificial intelligence in dermatology
3.5.3.8 Applications:
Chapter 4 U.S. Dermatology Market: Segment Analysis by Test Type
4.1 U.S. Dermatology Market: Test Type Movement Analysis
4.2 Skin Biopsy
4.2.1 Skin Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
4.3 Dermatoscopy
4.3.1 Dermatoscopy market estimates and forecasts, 2018 - 2030 (USD Million)
4.4 Diagnostic Imaging
4.4.1 Diagnostic imaging market estimates and forecasts, 2018 - 2030 (USD Million)
4.5 Lymph Node Biopsy
4.5.1 Lymph Node Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5 Canada Dermatology Market: Segment Analysis by Test Type
5.1 Canada Dermatology Market: Test Type Movement Analysis
5.2 Skin Biopsy
5.2.1 Skin Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
5.3 Dermatoscopy
5.3.1 Dermatoscopy market estimates and forecasts, 2018 - 2030 (USD Million)
5.4 Diagnostic Imaging
5.4.1 Diagnostic imaging market estimates and forecasts, 2018 - 2030 (USD Million)
5.5 Lymph Node Biopsy
5.5.1 Lymph Node Biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 6 U.S. Dermatology Market: Segment Analysis by Facility Type
6.1 U.S. Dermatology Market: Facility Type Movement Analysis
6.2 Standalone Practices
6.2.1 Standalone Practices market estimates and forecasts, 2018 - 2030 (USD Million)
6.3 Multispecialty Clinics
6.3.1 Multispecialty Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
6.4 Dermatology Groups
6.4.1 Dermatology Groups market estimates and forecasts, 2018 - 2030 (USD Million)
6.5 Hospital Outpatient Departments
6.5.1 Hospital Outpatient Departments market estimates and forecasts, 2018 - 2030 (USD Million)
6.6 Others (Integrated Delivery Network)
6.6.1 Others (Integrated Delivery Network) market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7 Canada Dermatology Market: Segment Analysis by Facility Type
7.1 Canada Dermatology Market: Facility Type Movement Analysis
7.2 Standalone Practices
7.2.1 Standalone Practices market estimates and forecasts, 2018 - 2030 (USD Million)
7.3 Multispecialty Clinics
7.3.1 Multispecialty Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
7.4 Dermatology Groups
7.4.1 Dermatology Groups market estimates and forecasts, 2018 - 2030 (USD Million)
7.5 Hospital Outpatient Departments
7.5.1 Hospital Outpatient Departments market estimates and forecasts, 2018 - 2030 (USD Million)
7.6 Others (Integrated Delivery Network)
7.6.1 Others (Integrated Delivery Network) market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8 U.S. Dermatology Market: Segment Analysis by Age-group
8.1 U.S. Dermatology Market: Age-group Movement Analysis
8.2 0-19
8.2.1 0-19 market estimates and forecasts, 2018 - 2030 (USD Million)
8.2.2 Male 0-19 market estimates and forecasts, 2018 - 2030 (USD Million)
8.2.3 Female 0-19 market estimates and forecasts, 2018 - 2030 (USD Million)
8.3 20-39
8.3.1 20-39 Market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.2 Male 20-39 market estimates and forecasts, 2018 - 2030 (USD Million)
8.3.3 Female 20-39 market estimates and forecasts, 2018 - 2030 (USD Million)
8.4 40-59
8.4.1 40-59 Market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.2 Male 40-59 market estimates and forecasts, 2018 - 2030 (USD Million)
8.4.3 Female 40-59 market estimates and forecasts, 2018 - 2030 (USD Million)
8.5 60-64
8.5.1 60-64 Market estimates and forecasts, 2018 - 2030 (USD MILLION)
8.5.2 Male 60-64 market estimates and forecasts, 2018 - 2030 (USD Million)
8.5.3 Female 60-64 market estimates and forecasts, 2018 - 2030 (USD Million)
8.6 65-74
8.6.1 65-74 Market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.2 Male 65-74 market estimates and forecasts, 2018 - 2030 (USD Million)
8.6.3 Female 65-74 market estimates and forecasts, 2018 - 2030 (USD Million)
8.7 75-84
8.7.1 75-84 Market estimates and forecasts, 2018 - 2030 (USD Million)
8.7.2 Male 75-84 market estimates and forecasts, 2018 - 2030 (USD Million)
8.7.3 Female 75-84 market estimates and forecasts, 2018 - 2030 (USD Million)
8.8 85 & above
8.8.1 85 & above Market estimates and forecasts, 2018 - 2030 (USD Million)
8.8.2 Male 85 & above market estimates and forecasts, 2018 - 2030 (USD Million)
8.8.3 Female 85 & above market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 9 Canada Dermatology Market: Segment Analysis by Age-group
9.1 Canada Dermatology Market: Age-group Movement Analysis
9.2 0-19
9.2.1 0-19 market estimates and forecasts, 2018 - 2030 (USD Million)
9.2.2 Male 0-19 market estimates and forecasts, 2018 - 2030 (USD Million)
9.2.3 Female 0-19 market estimates and forecasts, 2018 - 2030 (USD Million)
9.3 20-39
9.3.1 20-39 Market estimates and forecasts, 2018 - 2030 (USD Million)
9.3.2 Male 20-39 market estimates and forecasts, 2018 - 2030 (USD Million)
9.3.3 Female 20-39 market estimates and forecasts, 2018 - 2030 (USD Million)
9.4 40-59
9.4.1 40-59 Market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.2 Male 40-59 market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.3 Female 40-59 market estimates and forecasts, 2018 - 2030 (USD Million)
9.5 60-64
9.5.1 60-64 Market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.2 Male 60-64 market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.3 Female 60-64 market estimates and forecasts, 2018 - 2030 (USD Million)
9.6 65-74
9.6.1 65-74 Market estimates and forecasts, 2018 - 2030 (USD Million)
9.6.2 Male 65-74 market estimates and forecasts, 2018 - 2030 (USD Million)
9.6.3 Female 65-74 market estimates and forecasts, 2018 - 2030 (USD Million)
9.7 75-84
9.7.1 75-84 Market estimates and forecasts, 2018 - 2030 (USD Million)
9.7.2 Male 75-84 market estimates and forecasts, 2018 - 2030 (USD Million)
9.7.3 Female 75-84 market estimates and forecasts, 2018 - 2030 (USD Million)
9.8 85 & above
9.8.1 85 & above market estimates and forecasts, 2018 - 2030 (USD Million)
9.8.2 Male 85 & above market estimates and forecasts, 2018 - 2030 (USD Million)
9.8.3 Female 85 & above market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 10 Competitive Analysis
10.1 Company Profiles
10.1.1 Firefly
10.1.1.1 Company overview
10.1.1.2 Financial performance
10.1.1.3 Product Benchmarking
10.1.2 SkinIO
10.1.2.1 Company overview
10.1.2.2 Financial performance
10.1.2.3 Product Benchmarking
10.1.2.4 Strategic Initiative
10.1.3 Canfield Scientific, Inc.
10.1.3.1 Company overview
10.1.3.2 Financial performance
10.1.3.3 Product Benchmarking
10.1.3.4 Strategic Initiative
10.1.4 FotoFinder Systems, Inc.
10.1.4.1 Company overview
10.1.4.2 Financial performance
10.1.4.3 Product Benchmarking
10.1.5 3GEN
10.1.5.1 Company overview
10.1.5.2 Financial performance
10.1.5.3 Product Benchmarking
10.1.6 MetaOptima
10.1.6.1 Company overview
10.1.6.2 Financial performance
10.1.6.3 Product Benchmarking
10.1.6.4 Strategic Initiative
10.1.7 Agilent Technologies
10.1.7.1 Company overview
10.1.7.2 Financial performance
10.1.7.3 Product Benchmarking
10.1.7.4 Strategic Initiative
10.1.8 SkinVision
10.1.8.1 Company overview
10.1.8.2 Financial performance
10.1.8.3 Product Benchmarking
10.1.9 Speclipse, INC.
10.1.9.1 Company overview
10.1.9.2 Financial performance
10.1.9.3 Product Benchmarking
10.1.10 Skin Analytics
10.1.10.1 Company overview
10.1.10.2 Financial performance
10.1.10.3 Product Benchmarking
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers